Cytori Therapeutics (NASDAQ: CYTX) and Inogen (NASDAQ:INGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Cytori Therapeutics and Inogen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytori Therapeutics 0 1 1 0 2.50
Inogen 0 3 2 1 2.67

Cytori Therapeutics presently has a consensus target price of $3.65, indicating a potential upside of 1,116.67%. Inogen has a consensus target price of $98.50, indicating a potential downside of 17.30%. Given Cytori Therapeutics’ higher probable upside, analysts clearly believe Cytori Therapeutics is more favorable than Inogen.

Risk & Volatility

Cytori Therapeutics has a beta of 3.21, suggesting that its stock price is 221% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Cytori Therapeutics and Inogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytori Therapeutics -367.33% -228.21% -69.19%
Inogen 11.36% 13.37% 11.16%

Insider & Institutional Ownership

7.4% of Cytori Therapeutics shares are held by institutional investors. 1.9% of Cytori Therapeutics shares are held by insiders. Comparatively, 5.3% of Inogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Cytori Therapeutics and Inogen’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytori Therapeutics $4.66 million 2.26 -$22.04 million ($0.90) -0.33
Inogen $202.83 million 12.25 $20.51 million $1.23 96.83

Inogen has higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Summary

Inogen beats Cytori Therapeutics on 11 of the 14 factors compared between the two stocks.

About Cytori Therapeutics

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

About Inogen

Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.